ECTS2013 Poster Presentations Osteoporosis: treatment (64 abstracts)
Estimation of vertebral and femoral strength during the first three years of denosumab therapy using an alternative smooth non-linear finite element methodology
Philippe Zysset 1 , Dieter Pahr 2 , Klaus Engelke 3, , Harry Genant 5 , Michael McClung 6 , David Kendler 7 , Christopher Recknor 8 , Michael Kinzl 2 , Jakob Schwiedrzik 1 , Oleg Museyko 9 , Andrea Wang 10 & Cesar Libanati 10
1University of Bern, Bern, Switzerland; 2Vienna University of Technology, Vienna, Austria; 3University of Erlangen, Erlangen, Germany; 4Synarc Germany, Hamburg, Germany; 5UCSF and Synarc, San Francisco, California, USA; 6Oregon Osteoporosis Center, Portland, Oregon, USA; 7University of British Columbia, Vancouver, British Columbia, Canada; 8United Osteoporosis Centers, Gainesville, Georgia, USA; 9University of Erlangen-Nuremberg, Erlangen-Nuremberg, Germany; 10Amgen Inc., Thousand Oaks, California, USA.
Denosumab subcutaneous administration every 6 months reduced the incidence of new fractures in postmenopausal women with osteoporosis by 68% at the spine and 40% at the hip over 36 months compared with placebo in the FREEDOM study (Cummings et al., NEJM, 2009:361:756). This efficacy was supported by differential improvements from baseline in vertebral and femoral strength at 36 months (18.2 and 8.6%, respectively) estimated by an established voxel-based finite element (FE) methodology (Keaveny et al., ASBMR, 2010:OP1099).
Since FE analyses rely on the choice of meshes, material properties, and boundary conditions, the aim of this study was to independently confirm and compare the effects of denosumab on vertebral and femoral strength during the FREEDOM trial using an alternative smooth FE methodology.
QCT data for two lumbar vertebrae and the proximal femur were obtained at baseline, 12, 24, and 36 months from 51 treated (denosumab) and 47 control (placebo) subjects from FREEDOM. The QCT images were segmented and converted into smooth FE models to compute bone strength. L1 and L2 were virtually loaded in axial compression and the proximal femora in both fall and stance configurations.
For L1 and L2, strength of the denosumab group increased on average by 11.3, 14.4, and 17.6% from baseline at 12, 24, and 36 months, respectively (P<0.0001). Femoral strength of the denosumab group increased significantly in the fall configuration to 4.3, 5.1, and 7.2% above baseline at 12, 24, and 36 months, respectively (P<0.0001). Similar improvements were observed in the stance configuration. Differences with the decreasing strengths of placebo were highly significant after 12 months (P<0.0001).
We confirmed the significant improvements in vertebral and femoral strength previously observed with denosumab therapy using an alternative smooth FE methodology. The estimated increases in strength with denosumab and decreases with placebo were highly consistent between both FE techniques.
Article tools
My recent searches
My recently viewed abstracts
Authors
Bone Abstracts
ISSN 2052-1219 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more